主页 /
搜索结果：“ab fubinaca”

“ab fubinaca”的搜索结果

Quick View
Lyn-IN-1

Catalog No. A16265
Quick View

添加到收藏
dual Bcr-Abl/Lyn 抑制剂

Lyn-IN-1是一种有效的选择性Bcr-Abl/Lyn双重抑制剂，摘自专利WO2014169128A1。了解更多

Bulk Inquiry
Quick View
Dasatinib hydrochloride

Catalog No. A15060
Quick View

添加到收藏
Src 抑制剂

Dasatinib hydrochloride是一种有效的Abl/Src双重抑制剂，IC50分别<1 nM/0.8 nM。还可以抑制c-Kit（WT/c-Kit（D816V），IC50为79 nM/37 nM。有效，选择性Raf激酶抑制剂能够抑制野生型B-Raf，B-RafV600E和c -Raf的IC50值分别为3.2、0.8和5.0 nM。了解更多

Bulk Inquiry
Quick View
1-NA-PP1

Catalog No. A13232
Quick View

添加到收藏
Src Kinase 抑制剂

1-NA-PP1是v-Src和c-Fyn以及c-Abl的选择性抑制剂。了解更多

Bulk Inquiry Free Sample
Quick View
XL-228

Catalog No. A13069
Quick View

添加到收藏
IGF-1R, Aurora, FGFR, ABL, SRC 抑制剂

XL228是靶向IGF1R，AURORA激酶，FGFR1-3，ABL和SRC家族激酶的蛋白激酶抑制剂。XL228是一种Aurora A抑制剂（IC50，f3 nmol/L），对ABL1（Ki，5 nmol/L）以及BCR-ABL1 T315I（Ki，1.4 nmol/L）激酶显示出有效的生化活性。了解更多

Bulk Inquiry Free Sample
Quick View
PP1

Catalog No. A12724
Quick View

添加到收藏
Src 抑制剂

PP1是Src家族酪氨酸激酶的有效抑制剂。抑制p56lck和p59fynT（IC50值分别为5和6 nM）。在ZAP-70和JAK2上显示的选择性> 8000倍。还适度抑制p38，CSK，PDGF受体，RET衍生的癌蛋白，c-Kit和Bcr-Abl。了解更多

Bulk Inquiry Free Sample
Quick View
PP121

Catalog No. A11207
Quick View

添加到收藏
PI3K 抑制剂

PP121是一种作用于PDGFR，Hck，mTOR，VEGFR2，Src和Abl的多靶点抑制剂，IC50分别为2 nM，8 nM，10 nM，12 nM，14 nM和18 nM，也抑制DNA-PK，IC50为60 nM。了解更多

Bulk Inquiry Free Sample
Quick View
NVP-BHG712

Catalog No. A10661
Quick View

添加到收藏
EphB4 抑制剂

NVP-BHG712是EphB4激酶的选择性抑制剂，在体外对EphB4的选择性超过40多种其他激酶（包括FGFR3）。了解更多

Product Citations (1)

Bulk Inquiry Free Sample
- Y Kaibori, .et al. EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ERK/RSK pathway regulates M-phase progression via maintenance of cortical rigidity, the FASEB Journal, 2019, Jan 22:fj201801519RR PMID: 30668924
Quick View
Dasatinib (BMS-354825)

Catalog No. A10290
Quick View

添加到收藏
Abl-Src 抑制剂

Dasatinib (BMS-354825)是一种口服多BCR/ABL和Src家族酪氨酸激酶抑制剂。Dasatinib (BMS-354825)的主要靶标是BCR/ABL，Src，c-Kit，ephrin受体和其他几种酪氨酸激酶，但不是erbB激酶，例如EGFR或Her2。了解更多

Product Citations (10)

Bulk Inquiry Free Sample
- Chihiro Motozono, .et al. The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition, Nat Commun, 2022, Sep 21;13(1):5440 PMID: 36130929
- Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
- David E J Klawon, .et al. Altered selection on a single self-ligand promotes susceptibility to organ-specific T cell infiltration, J Exp Med, 2021, Jun 7;218(6) PMID: 33914024
- Reiko Watanabe, .et al. Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration, J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
- Li Li, .et al. Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1, Leukemia Res, 2019, 78:12-20 PMID: 30660961
- Sano T, .et al. Gliding Basal Cell Migration of the Urothelium during Wound Healing, Am J Pathol, 2018, Nov;188(11):2564-2573 PMID: 30121259
- Ines Peschel, .et al. FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia, Haematologica, 2017, Aug; 102(8): 1378-1389 PMID: 28522571
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277
- John D. Leonard, .et al. Identification of natural regulatory T cell epitopes reveals convergence on a dominant autoantigen, Immunity, 2017, Jul 18; 47(1): 107-117.e8 PMID: 28709804
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
Quick View
Saracatinib (AZD0530)

Catalog No. A10108
Quick View

添加到收藏
Src/Abl 抑制剂

Saracatinib (AZD0530)是一种高选择性，双特异性Src/Abl激酶抑制剂，对c-Src和Abl激酶的IC50分别为2.7和30 nM。了解更多

Product Citations (4)

Bulk Inquiry Free Sample
- Andromachi Lambrianidou, .et al. mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival, Cell Signal, 2021, Apr;80:109912 PMID: 33388443
- Chisato Naito, .et al. Facilitatory effects of fetuin-A on atherosclerosis, Atherosclerosis, 2016, Mar;246:344-51 PMID: 26828753
- Kenta Maruyama, .et al. 5-Azacytidine-induced Protein 2 (AZI2) Regulates Bone Mass by Fine-tuning Osteoclast Survival, J Biol Chem, 2015, Apr 10; 290(15): 9377-9386 PMID: 25691576
- Amanda L Jackson, .et al. Emerging therapies: angiogenesis inhibitors for ovarian cancer, Expert Opin Emerg Drugs, 2015, Jun;20(2):331-46 PMID: 26001052